EMA Authorised: Dazublys (trastuzumab) — CuraTeQ Biologics s.r.o

View source ↗

Summary

Authorised monoclonal antibody therapy trastuzumab (Dazublys) for breast and stomach neoplasms in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Dazublys (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Stomach Neoplasms. MAH: CuraTeQ Biologics s.r.o. Decision date: 19/03/2026